Blackhawk Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Blackhawk Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-541	Closed	-$245K	–	163
2025 Q4	$245K	Sell	541 -6	-1%	-$2.59K	0.09%	142
2025 Q3	$214K	Buy	+547	New	+$229K	0.08%	145
2022 Q1	–	Sell	-945	Closed	-$208K	–	105
2021 Q4	$208K	Buy	+945	New	+$184K	0.13%	88
2021 Q3	–	Sell	-1,022	Closed	-$220K	–	114
2021 Q2	$220K	Buy	+1,022	New	+$214K	0.15%	93
2018 Q3	–	Sell	-295	Closed	-$48K	–	274
2018 Q2	$48K	Hold	295	–	–	0.05%	167
2018 Q1	$48K	Sell	295 -475	-62%	-$77.6K	0.04%	170
2017 Q4	$115K	Buy	+770	New	+$114K	0.1%	113

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Blackhawk Capital Partners's VRTX Position: Q1 2026 in Review

Blackhawk Capital Partners sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 541 shares — an estimated $245K sold.

Blackhawk Capital Partners first reported a position in VRTX in Q4 2017 and held it in 7 quarters. The position peaked at $245K in Q4 2025. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Blackhawk Capital Partners reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Blackhawk Capital Partners sold 541 Vertex Pharmaceuticals shares in Q1 2026, an estimated $245K.
Blackhawk Capital Partners first reported a position in Vertex Pharmaceuticals in Q4 2017 and held it in 7 quarters.
Blackhawk Capital Partners's Vertex Pharmaceuticals position peaked at $245K in Q4 2025.
1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Blackhawk Capital Partners's 13F filing for Q1 2026, filed 5 May 2026.